AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

  1. Romero Bogado, M. L. C. 12
  2. Steiner, M. 12
  3. Cobo-Ibáñez, T. 12
  4. Gómez, A. 12
  5. Paredes Romero, B. 12
  6. Thuissard Vasallo, I. 2
  7. Andreu Vazquez, C. 2
  8. Esteban Vazquez, A. V. 1
  9. Matias de la Mano, M. A. 34
  10. Cebrián Méndez, L. 34
  11. Garcia Yubero, C. 12
  12. Esteban-Ortega, M. D. M. 12
  13. Maceñido Marcos, N. 12
  14. Pajares Villarroya, R. 12
  15. Arribas Lopez, M. D. R. 12
  16. Esteban Alba, C. 4
  17. Martinez Hernandez, A. 12
  18. Guillen Santos, R. 1
  19. Garcia, I. 1
  20. Navio Marco, M. T. 34
  21. Muñoz-Fernández, S. 12
  1. 1 Hospital Infanta Sofia
    info

    Hospital Infanta Sofia

    Madrid, España

    ROR https://ror.org/05dfzd836

  2. 2 Universidad Europea de Madrid
    info

    Universidad Europea de Madrid

    Madrid, España

    ROR https://ror.org/04dp46240

  3. 3 Hospital Infanta Leonor
    info

    Hospital Infanta Leonor

    Madrid, España

    ROR https://ror.org/05nfzf209

  4. 4 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

Mostrar afiliaciones +
Revista:
Annals of the Rheumatic Diseases

ISSN: 0003-4967,  1468-2060

Año de publicación: 2023

Volumen: 82

Número: Suppl 1

Páginas: 1907.1-1907

Tipo: Artículo

DOI: 10.1136/ANNRHEUMDIS-2023-EULAR.2364 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Annals of the Rheumatic Diseases

Resumen

Background The disease modifying antirheumatic drugs (DMARD) impair the immune response of patients with immune-mediated inflammatory diseases (IMID).Objectives To analyze the seroprevalence of SARS-CoV-2 in patients with IMID treated with biological disease modifying antirheumatic drugs (bDMARD) or targeted synthetic (tsDMARD).Methods An ambispective cross-sectional study was performed in patients with IMID treated with bDMARD or tsDMARD. Seroprevalence was compared by measuring IgG against SARS-CoV-2 between October 2020 and May 2021.Results A total of 550 patients with IMID were studied, all of them on bDMARD or tsDMARD therapy, none of them vaccinated at that time against SARS-CoV-2. Patients receiving anti-TNFα therapy had a higher seroprevalence than other biologic and synthetic targeted therapies (OR= 1.792; 95% CI 1.088-2.951; p= 0.021).Patients with bDMARD or tsDMARD treated concomitantly with some type of conventional synthetic DMARD (csDMARD) presented a lower seroprevalence compared to patients treated in monotherapy, 10.7 vs. 19.9% (p= 0.003). When analyzing the treatments with the different csDMARD separately (methotrexate, leflunomide, sulfasalazine, azathioprine, hydroxychloroquine and the others), methotrexate was determined to influence in a lower seroprevalence, compared to those who did not receive any csDMARD, 9.8 vs 19.9% (OR= 0.439, 95% CI 0.232-0.828; p= 0.011). When evaluating the influence of methotrexate on seroprevalence among the different groups of bDMARD or tsDMARD, a lower seroprevalence was demonstrated in the group of patients receiving anti-TNFα and methotrexate in combination, versus patients on this bDMARD in monotherapy, 10.1 vs 24.1% (OR= 0.355, 95% CI 0.165 - 0.764; p=0.006). No significant differences were identified with the other bDMARD.Regarding the patients’ IMIDs, no differences in seroprevalence were observed when compared by disease groups with each other.Conclusion Seroprevalence in the group of patients with IMID is influenced according to the therapy received, being higher in patients receiving anti-TNFα monotherapy, but significantly lower if concomitant to this drug they receive methotrexate. These differences are not seen with the other b/tsDMARD and csDMARD.

Referencias bibliográficas

  • [1]Muñoz-Fernández S, Cebrian L, Thuissard IJ, Martina Steiner M, García-Yubero C, Esteban AV et al. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study. J Clin Reumatol. 2022 Mar 1; 28(2): e348-e352.
  • [2]Favalli EG, Gobbini A, Bombaci M, Maioli G, et al. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front Med (Lausana), March 2022.
  • [3]Simon D, Tascilar K, Kleyer A, Fagni F, Krönke G, Médeet C et al. Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARSCoV- 2 in an unvaccinated cohort. Arthritis & Rheumatology Vol. 74, No. 5, May 2022, pp 783–790